{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-015355","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.656708+00:00","generated_at":"2026-05-19T04:34:04.206843+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Processa grants Intact exclusive option to license PCS12852 for up to $452.5M milestones plus royalties","bullets":["Near-term payments: $2.5M option exercise fee plus 3.5% equity stake in Intact upon closing.","Up to $20M in development/regulatory milestones and over $432.5M in commercial milestones on net sales.","Double-digit royalty on worldwide net sales (ex-South Korea); Processa must share 60% of cash payments with licensor Yuhan.","PCS12852 is a Phase 2-ready 5-HT4 agonist for diabetic gastroparesis with positive Phase 2a safety/efficacy data.","Definitive license agreement subject to 120-day diligence, extension for $30K, and Yuhan amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-015355","json":"https://secwatch.observer/filing/0001641172-25-015355.json","markdown":"https://secwatch.observer/filing/0001641172-25-015355.md","text":"https://secwatch.observer/filing/0001641172-25-015355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/0001641172-25-015355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:34:04.206843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}